Naltrexone-induced alterations in human ethanol intoxication. 1994

R M Swift, and W Whelihan, and O Kuznetsov, and G Buongiorno, and H Hsuing
Department of Psychiatry and Human Behavior, Brown University Medical School, Providence, RI.

OBJECTIVE Outpatient clinical trials with an opioid antagonist, naltrexone, found that this agent reduces relapse drinking in abstinent alcoholics. It is unknown which aspects of intoxication may be affected by naltrexone. The authors investigated the effects of naltrexone on several subjective and objective measures of ethanol intoxication. METHODS In a double-blind crossover study, 19 nonalcoholic drinkers received a regimen of naltrexone, 50 mg p.o., or placebo on two different occasions, each time followed by a standard, intoxicating dose of ethanol. Subjective and objective measures of intoxication including mood, physical sensations, performance changes, and ethanol pharmacokinetics were determined. As a control for naltrexone effects, 12 additional subjects received naltrexone or placebo followed by a non-intoxicating, "placebo" dose of ethanol. RESULTS Naltrexone augmented certain sedative and discriminant effects of ethanol and reduced positive reinforcing effects without affecting psychomotor performance or ethanol pharmacokinetics. Naltrexone had minimal effects in subjects receiving placebo ethanol. CONCLUSIONS The data are compatible with the clinical findings and suggest that the reduction in ethanol consumption by alcoholics following naltrexone administration may occur because of greater subjective intoxication, greater aversive effects, or less positive reinforcement from ethanol.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009271 Naltrexone Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. Antaxone,Celupan,EN-1639A,Nalorex,Naltrexone Hydrochloride,Nemexin,ReVia,Trexan,EN 1639A,EN1639A
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011597 Psychomotor Performance The coordination of a sensory or ideational (cognitive) process and a motor activity. Perceptual Motor Performance,Sensory Motor Performance,Visual Motor Coordination,Coordination, Visual Motor,Coordinations, Visual Motor,Motor Coordination, Visual,Motor Coordinations, Visual,Motor Performance, Perceptual,Motor Performance, Sensory,Motor Performances, Perceptual,Motor Performances, Sensory,Perceptual Motor Performances,Performance, Perceptual Motor,Performance, Psychomotor,Performance, Sensory Motor,Performances, Perceptual Motor,Performances, Psychomotor,Performances, Sensory Motor,Psychomotor Performances,Sensory Motor Performances,Visual Motor Coordinations
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D003071 Cognition Intellectual or mental process whereby an organism obtains knowledge. Cognitive Function,Cognitions,Cognitive Functions,Function, Cognitive,Functions, Cognitive
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

R M Swift, and W Whelihan, and O Kuznetsov, and G Buongiorno, and H Hsuing
January 1986, Psychopharmacology,
R M Swift, and W Whelihan, and O Kuznetsov, and G Buongiorno, and H Hsuing
January 1991, Alcohol and alcoholism (Oxford, Oxfordshire). Supplement,
R M Swift, and W Whelihan, and O Kuznetsov, and G Buongiorno, and H Hsuing
January 1996, Alcohol (Fayetteville, N.Y.),
R M Swift, and W Whelihan, and O Kuznetsov, and G Buongiorno, and H Hsuing
January 1980, Advances in experimental medicine and biology,
R M Swift, and W Whelihan, and O Kuznetsov, and G Buongiorno, and H Hsuing
September 1973, The Journal of pediatrics,
R M Swift, and W Whelihan, and O Kuznetsov, and G Buongiorno, and H Hsuing
June 2007, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
R M Swift, and W Whelihan, and O Kuznetsov, and G Buongiorno, and H Hsuing
December 2000, The Journal of surgical research,
R M Swift, and W Whelihan, and O Kuznetsov, and G Buongiorno, and H Hsuing
November 2006, Journal of psychiatry & neuroscience : JPN,
R M Swift, and W Whelihan, and O Kuznetsov, and G Buongiorno, and H Hsuing
January 1984, Polish journal of pharmacology and pharmacy,
R M Swift, and W Whelihan, and O Kuznetsov, and G Buongiorno, and H Hsuing
July 2003, Psychopharmacology,
Copied contents to your clipboard!